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190Objective: The proportion of patients who can be bridged with left ventricular assist devices to myocardial re-
covery and the long-term outcome of these patients is unknown.
Methods:We investigated the outcomes of patients bridged to recovery compared with those bridged to trans-
plantation. All left ventricular assist devices were implanted as a bridge to transplantation with a very proactive
program of promoting myocardial recovery. A total of 40 patients were bridged to recovery and 52 to transplan-
tation. Of the bridged to recovery (explanted) group, 33 were men (age, 32.8  11.8 years), 37 had dilated car-
diomyopathy (familial in 3, peripartum cardiomyopathy in 3) and 3 had myocarditis. Of the bridged to
transplantation (transplanted) group, 42 were men (age, 42.3  12.5 years; P<.0005 vs bridged to recovery).
The diagnosis was ischemic heart disease in 24, dilated cardiomyopathy in 21 (only 13 received drug therapy),
hypertrophic obstructive cardiomyopathy in 2, arrythmogenic right ventricular dysplasia in 2, myocarditis in 1,
and congestive heart disease in 2.
Results: The survival rate was 89.9%, 73.9%, and 73.9% and 80.4%, 78.3, and 78.3% in the explanted and
transplanted groups at 1, 5, and 7 years, respectively. In total, 12 (23%) patients bridged transplantation either
died from, or required ventricular assist device support, for primary graft failure. Of the explanted patients, 4
(10%) subsequently required transplantation at 34, 512, 1019, and 1213 days (2 died 25 and 1867 days
after transplantation and 2 were well after 1523 and 3199 days). The rate of transplant or ventricular assist
device-free survival less noncardiac death for the bridged to recovery and bridged to transplantation groups,
respectively, was 89.9%, 73.9%, and 73.9% and 80.4%, 78.3%, and 78.3% at 1, 3, and 7 years. At latest
follow-up (1394 1195 days for the bridged to recovery and 1913 941 days for the bridged to transplantation
group), 5 of the bridged to transplantation patients (9.6%) had malignancy, 34 (65.4%) had hypercholesterol-
emia, 25 (48.1%) had hypertension, and 7 (13.5%) had coronary disease. The creatinine was 125.5  43.5 vs
95.2  16.5 mmol/L for the bridged to transplantation and bridged to recovery groups (P<.001).
Conclusions: The outcome after explantation for myocardial recovery is comparable, if not better than, after
bridge to transplantation. (J Thorac Cardiovasc Surg 2012;144:190-6)Myocardial recovery from advanced heart failure after left
ventricular assist device (LVAD) support can occur1-4;
however, the incidence is generally considered low and
the degree of recovery rarely thought sufficient to allow
device removal.5-12 Furthermore, device removal is often
considered hazardous and the long-term outcome of pa-
tients after device removal unknown.
We have developed a strategy13 that aggressively pro-
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The Journal of Thoracic and Cardiovascular Surga combination of additional specific drug therapy,14-17
combined with regular testing of underlying myocardial
function with the LVAD turned off or essentially off.18,19
This strategy has resulted in a high rate of recovery in
patients with chronic heart failure secondary to dilated
cardiomyopathy (DCM) and has resulted in many
undergoing device explantation.20,21
The aim of the present study was first to review the effect
and results of an aggressive attempt at promoting myocar-
dial recovery in patients with advance heart failure on a total
bridge to transplant program and secondly to compare the
long-term outcomes of patients after device removal com-
pared with those progressing to heart transplantation from
the device as planned. This would help with future decisions
regarding the aggressiveness with which recovery is pro-
moted for such patients and the patient’s decision to un-
dergo explantation.
METHODS
A total of 195 patients received an LVAD as a bridge to transplantation
(BTT) at the Royal Brompton and Harefield National Health Service Trustery c July 2012
Abbreviations and Acronyms
BIVAD ¼ biventricular assist device
BTR ¼ bridge to recovery
BTT ¼ bridge to transplantation
DCM ¼ dilated cardiomyopathy
LVAD ¼ left ventricular assist device
PVAD ¼ paracorporeal ventricular assist device
RVAD ¼ right ventricular assist device
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All devices were implanted as per the intended bridge-to-transplant-only
government funding. During that period, of the 195 implanted patients,
83 (42.6%) died, 52 (26.7%) underwent transplantation, 40 (20.5%)
were explanted for myocardial recovery, and 20 (10.3%) were ongoing.
The actuarial survival rate for the overall program, censored at transplan-
tation or explantation, was 74.7%, 65.8%, and 56.2% at 30 days, 90
days, and 1 year, with a dramatic improvement over time. The 30-day,
90-day, and 1-year survival rate increased from 39.1%, 34.8%, and
27.8% for the 1995 to 1998 implants to 92.7%, 87.3%, and 76.3% for
the 2006 to 2009 implants.
The 92 patients who were either transplanted (n ¼ 52) or explanted for
myocardial recovery (n ¼ 40) were the subjects of the present study. Their
preoperative demographics, hemodynamics, and other clinical parameters
were reviewed, and their clinical course on the device and long-term out-
comes after either transplantation or explantation were studied. This cohort
was followed up for at least 30 days after transplantation (range, 594–4226;
mean, 1913 941) or explantation (range, 30–3451; mean, 1394 1195).
The patient records, charts, and our prospectively recorded databases were
reviewed.
Patients Bridged to Recovery
Of the initial cohort bridged to transplantation, 40 were explanted dur-
ing the study period after achieving sufficient improvement in myocardial
function to be judged explantable (ie, were ‘‘bridged to recovery’’). Of
these, 33 were men (age, 32.8  11.8 years; range, 15.7–58.3 years). Of
the 40 patients, 37 had nonischemic DCM and 3 had myocarditis
(Figure 1). Of the 37 patients with DCM, 3 had familial cardiomyopathy
and 3 had postpartum cardiomyopathy. Two patients had a biventricular as-
sist device (BIVAD) Levitronix (Thoratec, Pleasanton, Calif) for 26 and 58
days and 1 had extracorporeal membrane oxygenation for 6 days before
long-term device implantation (originally deemed too ill for long-term
device implantation). The preoperative details are listed in Table 1. Of
the patients who recovered, 18 had had a Heartmate I LVAD (Thoratec),
15 a Heartmate II (Thoratec), 3 a Jarvik 2000 (Jarvik Heart, New York,
NY), 1 a Heartware (HeartWare International, Framington, Mass), and 3
were bridged directly to recovery with a Levitronix device.
Five patients (12.5%) also required additional right ventricular assist
device (RVAD) support—1 Heartmate I patient required a Thoratec
RVAD (removed after 61 days) and 2 Heartmate I and 2 Heartmate II pa-
tients required a Levitronix RVAD (removed at 26.5  19.7 days).
Patients Bridged to Tranplantation
Although all patients were implanted as a bridge to transplantation, 52
patients were transplanted during the study period. Of the 52 patients, 42
were males (mean age, 42.3 12.5; range, 15–59 years at ventricular assist
device [VAD] implantation). The underlying diagnoses are shown in
Figure 1. Of the 52 patients, 24 had ischemic heart disease, 2 hypertrophic
obstructive cardiomyopathy, 2 arrythmogenic right ventricular dysplasia, 1
transposition of the great arteries (previous Mustard), 1 small apicalThe Journal of Thoracic and Caventriculoseptal defects, 1 myocarditis, and 21 DCM. Of the 21 patients
with DCM, 1 patient had developed DCM secondary to chemotherapy
for non-Hodgkin’s lymphoma and 2 had postpartum DCM.
Of the 21 patients with DCMwho did not recover andwere transplanted,
only 13 had any treatment or testing for recovery and the other 8 had no
attempt at inducing recovery (2 had had a short-term device, 3 had had a Jar-
vik 2000 at a point at which we did not have institutional review board ap-
proval to promote and test for recovery, 2 had a paracorporeal VAD (PVAD)
that we did not make any attempt to recover, and 1 had a BIVAD with sig-
nificant infection and hence went straight to transplantation).
One patient had a BioMedicus (Eden Prairie, Minn) and 3 a BIVAD
Levitronix before their long-term device implantation. The preoperative
variables are listed in Table 1. Of the patients, 21 received a Heartmate I
LVAD, 1 a combined Heartmate I LVAD and Thoratec PVAD RVAD, 6
had a PVAD LVAD, 6 had a PVAD BIVAD, 8 received a Jarvik 2000
LVAD, and 6 a Heartmate II LVAD. Of these patients, 4 (7.7%; 2 a Heart-
mate 1, 1 a Jarvik, and 1 a Heartmate II) also received a Levitronix RVAD
that was removed from 3 before transplantation. Of the 52 patients, 4
(7.7%) were bridged directly with a Levitronix to transplantation.Statistical Analysis
The data are expressed as the mean  standard deviation and the
minimum and maximum, unless stated otherwise. A nonparametric
Mann-WhitneyU test was used to compare the preimplantation clinical pa-
rameters between the BTT and BTR groups. The Kaplan-Meier method
was used to calculate the freedom from death and freedom from death/
recurrence of heart failure.RESULTS
The actuarial survival of the BTR and BTT groups is
shown in Figure 2.Course With Device and Outcome of Patients BTR
The overall duration of support for the 40 patients in the
BTR group was 331.6 223.4 days (for the 37 patients with
a long-term device, 355.8  214.5 days; for the 3 patients
bridged directly to recovery with a Levitronix device,
32.6  12.1 days).
Two Heartmate I patients and 1 Heartware patient re-
quired a device exchange during their period of support.
One patient had device failure of his Heartmate I and 1 pa-
tient of his Jarvik 2000 device (lead fracture) before explan-
tation. All patients had undergone implantation as a BTT
but all were considered ready for device explantation; sig-
nificant infection was also present at explantation in 6 pa-
tients and contributed to the decision to explant.
After explantation, the actuarial survival rate was 89.9%,
73.9%, and 73.9% at 1, 5, and 7 years, respectively
(Figure 2). There were 4 early deaths (10%). The first pa-
tient died 1 day after explantation. She had developed
heparin-induced thrombocytopenia antibodies that had
cleared. Thus, she received heparin for the explant that
was associated with a severe bradycardic episode. She
was extubated with minimal inotropic support with good
ventricular function when she developed supraventricular
and then intractable ventricular arrhythmias. An autopsy
showed granulomas suggestive of an allergic reactionrdiovascular Surgery c Volume 144, Number 1 191
FIGURE 1. Diagnoses at implantation in bridge to recovery (BTR) vs
bridge to transplantation (BTT) group. DCM, Dilated cardiomyopathy;
IHD, ischemic heart disease; HOCM, hyperobstructive cardiomyopathy;
ARVD, arrythmogenic right ventricular dysplasia; VSD, ventricular septal
device.
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recurrent heart failure a few hours after explantation;
extracorporeal membrane oxygenation was implanted,TABLE 1. Patient demographics before ventricular assist device implanta
Preoperative parameter Bridged to recovery (n ¼ 40)
Age (y) 32.8  11.8*
Gender
Male 33
Female 7
Diagnosis 37 DCM (including 3 familial and 3 postpa
3 myocarditis
Device 18 HMI; 15 HMII; 3 Jarvik; 1 Heartware; 3
IABP 10 (25%)
Ventilated 7 (17.5%)
Inotropes (n) 2.0  0.8
Preoperative device 2 BIVAD Levitronix; 1 ECMO
PCWP (mm Hg) 26.9  7.4
CI (L/min/m2) 1.6  0.6
PA systolic (mm Hg) 45.5  13.2y
PA mean (mm Hg) 32.7  6.9y
PA saturation (%) 42.7  12.7
Duration of heart failure (m) 25.8  50y
EDD (mm) 70.5  11.5
ESD (mm) 64.4  10.9
EF (%) 22  7.8
Creatinine (mmol/L)z 129.2  54.4 (range, 74–318)
Bilirubin (mmol/L)x 40.7  22.4 (range, 14–99)
Different distribution of diagnoses between groups might affect some of the other variabl
disease; HOCM, hypertrophic obstructive cardiomyopathy; ARVD, arrythmogenic right ve
poreal ventricular assist device; RVAD, right ventricular assist device; LVAD, left ventricul
ECMO, extracorporeal membrane oxygenation; PCWP, pulmonary capillary wedge pressur
systolic dimension; EF, ejection fraction. *P<.005. yP<.05. zNormal range, 60–110 mm
192 The Journal of Thoracic and Cardiovascular Surgbut he died after 9 days. The third had excellent signs
of recovery (ejection fraction, 61%; left ventricular
end-diastolic dimension, 41 mm; left ventricular end-
systolic dimension, 30 mm; myocardial volume oxygen
consumption, 27.4 mL/kg/min; and cardiac index, 4
L/min/m2); however, transesophageal echocardiography at
explantation showed new thrombus in the ascending aorta
around the coronary sinuses, which had disappeared by
the time the aortic root was opened and was assumed to
have gone down the coronary arteries. Subsequently, it
took several attempts to wean him from cardiopulmonary
bypass, and a Levitronix short-term LVAD was inserted.
By day 6, he was weaning from inotropes, extubated, and
no longer required hemofiltration. However, he experienced
intracerebral hemorrhage and died on day 14. The fourth
patient died 26 days after explantation. He had had reason-
able recovery but had had recurrent severe driveline infec-
tion (Enterobacter cloacae, Acinotabacter baumanii).
After explantation, he was extubated in the operating
room and initially did extremely well. However on day 3,
he was sitting out of bed opening his bowels when he be-
came very sweaty, tachycardic, and had ventricular fibrilla-
tion arrest. He required extracorporeal membrane
oxygenation insertion but had a poor neurologic recovery
and died on day 26.tion
Bridged to transplantation (n ¼ 52)
42.3  12.5
42
10
rtum); 24 IHD; 21 DCM; 2 HOCM; 2 ARVD; 1 transposition;
1 VSD; 1 myocarditis
Levitronix 21 HMI; 6 HMII; 1 HMI and PVAD RVAD; 12 PVAD
(6 LVAD and 6 BIVADs); 8 Jarvik; 4 Levitronix
27 (52%)
6 (11.5%)
1.9  1.1
3 BIVAD Levitronix; 1 BioMedicus
28.8  8.9
1.5  0.3
53.7  14.1
38.8  9.7
51.2  10
42.2  44.1
69.0  13.8
60.9  14.2
25  12
124.6  56.5 (range, 44–341)
43.2  34.9 (range, 5–197)
es (eg, ventricular dimensions). DCM, Dilated cardiomyopathy; IHD, ischemic heart
ntricular dysplasia; VSD, ventricular septal device; HM, Heartmate; PVAD, paracor-
ar assist device; BIVAD, biventricular assist device; IABP, intra-aortic balloon pump;
e; CI, cardiac index; PA, pulmonary artery; EDD, end-diastolic dimension; ESD, end-
ol/L. xNormal range, 5–17 mmol/L.
ery c July 2012
FIGURE 2. Actuarial survival of explanted (n ¼ 40) compared with
transplanted (n ¼ 52) groups. BTR, Bridge to recovery; BTT, bridge to
transplant.
Birks et al Cardiothoracic Transplantation
T
XThere were 4 late deaths, 1 at 2.3 years of lung carcinoma
in a smoker (who owned an English pub), 1 at 2.5 years of
a paracetemol overdose (at the time of the overdose, he was
physically very well, with an ejection fraction of 60%), and
1 at 7.3 years of recurrent heart failure, principally frommi-
tral regurgitation. The latter patient had had extremely good
quality of life until 7 years after explantation; he was 63
years old at the recurrence of heart failure and decided
not to undergo additional surgery. The fourth patient died
8 years after explantation at age 39 years and again had
had good quality of life for 7.3 years (holding 2 concurrent
active jobs). When he developed recurrent heart failure, his
body mass index was 36 kg/m2, and he was considered too
overweight by the multidisciplinary team for transplanta-
tion or BTT.
Course With Device and Outcomes of Patients BTT
The duration of support for the 52 patients in the BTT
group was 313  210 days (for the 48 patients bridged
with a long-term device, 333  206 days; and for the 4 pa-
tients bridged directly with a Levitronix device, 73.3 33.8
days). Two Heartmate I patients required device exchange
to a PVAD and 1 PVAD patient required a device exchange
during the period of support. Two patients had failure
of their Heartmate I before transplantation and were
maintained with the pneumatic console before urgent
transplantation.
After transplantation, the actuarial survival rate was
80.4%, 78.3%, and 78.3% at 1, 5, and 7 years, respectively
(Figure 2). There were 5 (9.6%) early, 5 (9.6%) midterm,
and 3 (5.8%) late deaths. Of the 5 early deaths, 1 was in
the operating room of primary graft failure, 3 were 2, 3,
and 4 days after transplantation of primary graft failure
(all 3 had received BIVAD support for the donor heart).
The fifth was from a mixture of primary graft failure and
gastrointestinal ischemia (in a patient who had had a Heart-
mate I) at 10 days after transplantation. Of the 5 midterm
deaths, 1 died at 38 days of primary graft failure (after a pe-
riod of BIVAD support for the transplanted heart, the donor
histologic examination subsequently showed earlyThe Journal of Thoracic and Cahypertrophic obstructive cardiomyopathy). A second died
at 82 days, a donor patent foramen ovale was closed 7
days after the transplant, precipitating donor right heart fail-
ure requiring a period of RVAD support. He ultimately died
of a large hemothorax from a line insertion. The third had
a significant degree of graft failure and received augmented
immunosuppression, resulting in sepsis and death at 102
days. A fourth patient required BIVAD support for 5 weeks
to the donor heart; however, when the BIVADwas removed,
he required additional inotropic/intra-aortic balloon pump
support and then developed sepsis and died at 108 days.
A fifth patient required an Abiomed pump in the donor heart
for primary graft failure. This was subsequently removed,
but he developed pneumonia and died at 125 days. There
were 3 late deaths; 1 at 1.8 years of motor neuron disease,
1 at 665 days of noncompliance, and 1 at 7.8 years of squa-
mous cell carcinoma of the scalp.
Failure of Explantation or Transplantation
In addition to the deaths, we compared the failure of the
explanted heart (ie, requiring transplantation) with failure
of the transplanted heart (ie, requiring VAD support).
Failure of Explanted Heart Requiring
Transplantation
Four patients (10%) required transplantation after
explantation. One Heartmate I patient had significant
device-related infection at explantation and hence was
very tachycardic after explantation. After 2 days of tachy-
cardia after explantation, he developed ventricular tachy-
cardia, the heart dilated, and he experienced cardiac arrest
requiring Levitronix VAD implantation. He was trans-
planted 32 days later; he was alive and well 4.2 years later.
Another patient with a Heartmate I device had a large ab-
dominal infection at explantation, contributing to the deci-
sion to explant him. He did well initially but slowly
developed recurrent heart failure and underwent transplan-
tation 1.4 years later. He did well after transplantation and
finally developed acute, followed by chronic, rejection
and died of a pulmonary embolus 7.4 years after transplan-
tation. A third patient did well after explantation but then
had an episode of significant alcohol consumption, trigger-
ing deterioration of his cardiac function. He was trans-
planted 2.8 years after explantation and was alive and
well 6 years after transplantation. A fourth patient remained
very well for 2.5 years after tying off of the Jarvik device.
She had had residual mitral regurgitation at the tying off
of the device that worsened with time, developing recurrent
heart failure after 2.5 years and undergoing transplantation
after 3.3 years. However, she had primary graft failure re-
quiring a BIVAD for the donor heart and died 25 days after
transplantation.
The rate of freedom from death or transplantation after
explantation was 89.9%, 69%, and 69% at 1, 5, and 7rdiovascular Surgery c Volume 144, Number 1 193
FIGURE 3. A, Freedom from death or transplantation for explanted (n¼ 40) compared with death or need for ventricular assist device (VAD) support for
transplanted (n¼ 52) group. B, Freedom from death or transplantation for explanted (n¼ 40) compared with death or need for VAD support for transplanted
(n¼ 52) group, excluding noncardiac death (ie, excluding deaths from lung carcinoma and paracetemol overdose in the bridge to recovery [BTR] group and
from motor neuron disease in the bridge to transplantation [BTT] group). NS, Not significant.
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death or transplantation after explantation, excluding non-
cardiac death, was 89.9%, 76.7%, and 76.7% at 1, 5, and
7 years, respectively (Figure 3, B).TABLE 2. Follow-up parameters at latest follow-up
Follow-up
parameter Bridged to recovery
Bridged to
transplantation
Follow-up period 1394  1195 (30–3451) 1913  941 (594–4226)
LVEDD (mm) 59.4  8.4* 50  6.1
LVESD (mm) 44.5  11.7* 32.1  6
EF (%) 57.4  17.4* 73.6  6.6
Creatinine (g/L) 92.7  18.5y 125.5  43.5
Bilirubin (g/L) 23.7  26.2 17.7  7.3
mVO2 (mL/kg/min) 26  6.4 Not done
Hyperlipidemia 0 (0) 34 (65.4%)
Hypertension 0 (0) 25 (48.1%)
Coronary disease 0 (0) 7 (13.5%)
Malignancy 0 (0) 5 (9.6%)
LVEDD, Left ventricular end-diastolic dimension; LVESD, left ventricular
end-systolic dimension; EF, ejection fraction;mVO2, myocardial volume oxygen con-
sumption. *P<.00005. yP<.0005.Failure of Transplanted Heart RequiringMechanical
Support
In total, 12 (23%) of the patients bridged to transplanta-
tion had significant primary graft failure requiring mechan-
ical support for the donor heart or resulting in the recipient’s
death. Eight of the deaths occurring after transplantation in
the BTT group were primarily from primary graft failure (7
required mechanical support for the donor heart and 1 died
of primary graft failure in the operating room). An addi-
tional 4 patients required a period of VAD support after
transplantation (ie, had had primary graft failure sufficient
to require a period of mechanical support for the donor
heart): 2, a BIVAD for 6 and 20 days; 1, a RVAD for 25
days; and 1, a LVAD for 14 days. The rate of freedom
from death or requirement for VAD support after transplan-
tation was 74.5%, 72.4%, and 72.4% at 1, 5, and 7 years,
respectively (Figure 3, A). The rate of freedom from death
or requirement for VAD support after transplantation,194 The Journal of Thoracic and Cardiovascular Surgexcluding noncardiac death, was 76.5%, 74.4%, and
74.4% at 1, 5, and 7 years, respectively (Figure 3, B).Postexplant and Post-Transplant Clinical Outcomes
In the surviving explant patients at latest follow-up,
a mean period of 1394  1195 days (range, 30–3451) afterery c July 2012
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sion was 59.4  8.4 mm, left ventricular end-systolic di-
mension was 44.5  11.7 mm, ejection fraction was
57.4%  17%, serum creatinine 95.2  16.5 mmol/L,
bilirubin 24.6 26.9 mmol/L (Table 2), and myocardial vol-
ume oxygen consumption was 26 6.4 mL/kg/min. No pa-
tients developed hypercholesterolemia, hypertension,
coronary disease, or malignancy.
In the surviving transplant patients at latest follow-up,
a mean period of 1913  941 days (range, 594–4226
days) after transplantation, the left ventricular end-
diastolic dimension was 50  6.1 mm, left ventricular
end-systolic dimension was 32.1  6.0 mm, ejection frac-
tion 73.6%  6.6%, creatinine was 125.5  43.5 mmol/L,
and bilirubin 17.7  7.3 mmol/L (Table 2). A total of
34 (65.4%) transplanted patients developed hypercholes-
terolemia, and 25 (48.1%) developed hypertension; 7 pa-
tients developed coronary disease, 5 of whom had only
mild disease. Five patients (9.6%) developed malignancy
(1 Epstein-Barr virus-induced lymphoproliferative disease,
1 carcinoma of the esophagus, 1 renal cell carcinoma, 1 skin
carcinoma, and 1 small cell carcinoma of the scalp).
DISCUSSION
We have compared for the first time the outcomes of
a large cohort of patients explanted for myocardial recovery
with the outcomes of patients transplanted on a device dur-
ing the same period. We demonstrated the significant effect
on a total mechanical circulatory support program of ag-
gressively promoting recovery and explanting patients.
We have also demonstrated comparable, if not better, sur-
vival and lower failure rates and a lower rate of longer
term complications in the explanted compared with the
transplanted group.
We have demonstrated the advantages and disadvantages
and benefits and risks of explantation of LVADs due to suf-
ficient myocardial recovery. The decision to explant can be
very difficult12,22 owing to the paucity of data currently
available. We have provided some long-term data and
hope to encourage programs to attempt recovery of their pa-
tients. We have also previously demonstrated the quality of
life of the explanted patients to be very good.23
Our data show a significant number of patients can be ex-
planted if recovery is aggressively promoted and tested for,
particularly patients with nonischemic cardiomyopathy. Al-
though all patients were implanted as a BTT, only 52 pa-
tients were transplanted during this 14-year period and 40
were explanted. Of the 21 patients with DCM who did not
recover and were transplanted, only 13 had received any
treatment or testing for recovery, and 8 had had no attempt
at inducing recovery. In contrast, 37 patients with DCM re-
covered and were explanted; thus, the rate of recovery in pa-
tients with DCM at our institution with an aggressive
attempt to induce remission of heart failure using drugsThe Journal of Thoracic and Caand testing18,19 was much greater than at other institutions
to date.20,21
During the study period, of all 195 implanted patients
with any diagnosis, 83 (42.6%) died, 52 (26.7%) were
transplanted, 40 (20.5%) were explanted for myocardial re-
covery, and 2 (10.3%) were still ongoing. Hence, of the 112
survivors, 40 (35.7%) were explanted, 52 (46.4%) were
transplanted, and 20 (17.9%) were ongoing (ie, outcome
unknown). This is a high proportion given that recovery
was only attempted in the patients with DCM.
The number of donor organs available for transplantation
is declining and is totally inadequate for the number of pa-
tients requiring transplantation. Thus, being able to explant
these patients is very important because such patients could
then avoid transplantation and the donor heart can be saved
for another patient. This is particularly important in the
United Kingdom, where funding is currently only available
for inserting these devices as a BTT and not as destination
therapy.
A better term than ‘‘myocardial recovery’’ might well be
remission of heart failure. We studied the effectiveness and
durability of that remission by considering the long-term
follow-up of a large group of explanted patients. Survival
was similar between the explanted and transplanted pa-
tients. There were 4 early deaths after explantation and 4
late deaths, 2 of which were not cardiac-related (carcinoma
of the lung and paracetemol overdose) and the other 2 were
very late (>7 years). Of the explanted patients, 4 required
transplantation, of whom 2 were alive and well at the last
follow-up, 1 survived 7.4 years with his transplanted heart,
and 1 died early after transplantation. The rate of failure of
the transplanted hearts was greater than that of the failure of
the explanted hearts (Figure 3). A striking finding was the
good functional capacity of the explanted group.
Several of the patients had significant driveline infection,
often contributing to the decision to explant. Infection can
make these patients tachycardic and vasoplegic and they
can require vasopressors, which can be detrimental to the
explanted heart, as can the tachycardia. One of the early
deaths appeared to be precipitated by tachycardia. We
changed our strategy over time to give these patients very
aggressive antibiotics (chosen according to driveline sensi-
tivities) around explantation, to give their b-blocker on the
morning of the explant to limit the tachycardia. We also de-
veloped a low threshold for hemofiltration of the patient for
a short period (usually about 12 hours) with the purpose of
cooling the patient and limiting the tachycardia.
In the long term, the transplanted patients started to en-
counter the typical complications that occur after transplan-
tation, often related to their immunosuppression. There was
a high incidence of hypertension and hyperlipidemia and
a significant amount of coronary disease and malignancy.
The creatinine at latest follow-up was also significantly
greater in the transplanted patients.rdiovascular Surgery c Volume 144, Number 1 195
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the best option, especially as the option to reinsert the de-
vice later or transplant them later exists. It is likely that their
overall lifespan would be significantly prolonged (either by
explantation alone or by a combination of both). Our data
also suggest that a significant number of explanted patients
are likely to never need a device or heart transplant.
Study Limitations
Although many of the patients with DCM were prospec-
tively studied as part of individual prospective studies,20,21
many others were not; thus, this was essentially
a retrospective analysis, although of the entire VAD
program. From December 1999 onward, all Heartmate I
and Heartmate II patients with DCM received an
aggressive attempt at inducing recovery, along with testing
of underlying myocardial function. However, this did not
occur before December 1999, and not all the patients
receiving other devices received such an aggressive attempt
at inducing recovery. Patients with other diagnoses did not
receive either testing or promotion of myocardial recovery.
Another limitation of the present study was the high rate of
primary graft failure in our cohort after transplantation.
There has been a 46% decline24 in the number of heart trans-
plants in the United Kingdom during the past 10 years, caus-
ing centers to use more marginal donors and resulting in
greater rates of primary graft failure in several UK centers,
including ours. This might have skewed the comparison of
survival after transplantation vs explantation.25
CONCLUSIONS
In conclusion, our results suggest that aggressively at-
tempting recovery can have a major effect on a BTT pro-
gram and its patients, managing to avoid transplantation
in a significant proportion. The outcomes of those who
are explanted were comparable, if not superior, to the out-
comes of those undergoing transplantation.
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